TY - JOUR
T1 - Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis
T2 - Update on recent mechanistic insights related to kidney physiology
AU - van Ruiten, Charlotte C.
AU - Hesp, Anne C.
AU - van Raalte, Daniël H.
N1 - Funding Information: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Publisher Copyright: © 2022 The Authors
PY - 2022/6
Y1 - 2022/6
N2 - Sodium glucose cotransporter-2 (SGLT2) inhibitors have acquired a central role in the treatment of type 2 diabetes, chronic kidney disease including diabetic kidney disease, and heart failure with reduced ejection fraction. SGLT2 inhibitors lower glucose levels by inducing glycosuria. In addition, SGLT2 inhibitors improve cardiovascular outcomes (3-point MACE), end-stage kidney disease, hospitalization for heart failure, and cardiovascular mortality in people with and without diabetes. The mechanisms underlying these benefits have been extensively investigated, but remain poorly understood. In this review, we first summarize recent trial evidence and subsequently focus on (1) the mechanisms by which SGLT2 inhibitors improve kidney outcomes and (2) the potential role of the kidneys in mediating the cardioprotective effects of SGLT2 inhibitors.
AB - Sodium glucose cotransporter-2 (SGLT2) inhibitors have acquired a central role in the treatment of type 2 diabetes, chronic kidney disease including diabetic kidney disease, and heart failure with reduced ejection fraction. SGLT2 inhibitors lower glucose levels by inducing glycosuria. In addition, SGLT2 inhibitors improve cardiovascular outcomes (3-point MACE), end-stage kidney disease, hospitalization for heart failure, and cardiovascular mortality in people with and without diabetes. The mechanisms underlying these benefits have been extensively investigated, but remain poorly understood. In this review, we first summarize recent trial evidence and subsequently focus on (1) the mechanisms by which SGLT2 inhibitors improve kidney outcomes and (2) the potential role of the kidneys in mediating the cardioprotective effects of SGLT2 inhibitors.
KW - Chronic kidney disease
KW - Kidney outcomes
KW - SGLT2 inhibitor
KW - Sodium handling
KW - Tubuloglomerular feedback
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85127924066&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ejim.2022.03.031
DO - https://doi.org/10.1016/j.ejim.2022.03.031
M3 - Review article
C2 - 35414444
SN - 0953-6205
VL - 100
SP - 13
EP - 20
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
ER -